Form 4: Tevogen Bio Holdings CEO Ryan H. Saadi Increases Stake in Company
SEC Form 4 Filing
CEO Ryan H. Saadi reports purchasing additional shares of Tevogen Bio Holdings, increasing his direct holdings.
Summary
- On June 5, 2024, Ryan H. Saadi, CEO of Tevogen Bio Holdings Inc., purchased 2,607.322 shares of common stock at a weighted average price of $0.7671 per share.
- The shares were bought in multiple transactions with prices ranging from $0.7635 to $0.7671.
- Following the transaction, Saadi directly owns 118,252,659.322 shares of Tevogen Bio Holdings Inc.
- Saadi also indirectly owns 193,924 shares through his wife.
Sentiment
Score: 6
Explanation: The sentiment is neutral. Insider buying can be a positive signal, but the purchase is relatively small compared to the CEO's existing holdings. It's a routine filing, so it doesn't drastically shift sentiment.
Positives
- The CEO's purchase of additional shares could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- Shareholders may view the CEO's purchase as a positive signal, potentially increasing confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of the transaction where Ryan H. Saadi purchased shares of common stock. |
| 06/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.